The majority of people with diabetes live in low- and middle-income
countries.1 Access to reliable and affordable supplies of
insulin is a challenge for many. In fact, it is estimated that 50
million people lack access to insulin worldwide.2
Novo Nordisk has addressed this challenge since we introduced our Differential Pricing Policy for Least Developed Countries (LDCs) in 2001. Our continued commitment to having a low-cost insulin in our product portfolio and to producing and making human insulin available for years to come, is formulated in our Access to Insulin Commitment. With the expanded scope in 2019, the Access to Insulin Commitment today covers a total of 78 countries, home to a third of the world’s diabetes population1, as well as selected humanitarian organisations.
The commitment builds on the following principles:
An estimated 2.9 million people were treated with insulin under this commitment in 2019, of which approximately 200,000 people were reached through sales to humanitarian organisations. In 2019, the average price the insulin was sold at under the commitment was 2.9 USD per vial, equalling 12 cents per patient per day.3 Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated additional 2.2 million people in 2019.
1. International Diabetes Federation. IDF Diabetes Atlas, 8th edition, 2017
2. ACCISS. Fact Sheet on Inequities and Inefficiencies in the global insulin market. Amsterdam: Health Action International; 2015. Retrieved from:
3. Assuming average daily dose of 40 IU, as per WHO, Drug and Therapeutic Committee - A Practical Guide, 2003, Annex 6.1.